1
|
Gharaibeh L, Liswi M, Al-Ajlouni R, Shafei D, Fakheraldeen RE. Community Pharmacists' Readiness for Breast Cancer Mammogram Promotion: A National Survey from Jordan. J Multidiscip Healthc 2024; 17:4475-4489. [PMID: 39308798 PMCID: PMC11416785 DOI: 10.2147/jmdh.s471151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 08/28/2024] [Indexed: 09/25/2024] Open
Abstract
Purpose Mammography is the gold standard screening technique for early detection of breast cancer. This study aimed to assess the knowledge of community pharmacists of different aspects emphasized by the JBCP programs. This study also identifies the attitudes and barriers towards promoting early detection services. Patients and Methods This study was a cross-sectional survey of community pharmacists in Jordan. Pharmacists were randomly selected and asked to complete an electronic questionnaire. Inclusion criteria: a pharmacist with a bachelor's degree or higher and registered at the JPA working in a community pharmacy. The questionnaire included demographic and socioeconomic information, knowledge, attitudes towards breast cancer screening mammography services, and barriers towards participation in the promotion of these services. Results A total of 1,088 community pharmacists were approached, 1,000 (91.8%) completed the questionnaire. Participants had an average age of 34 years ± 10.8 and average experience of 9.1 ± 9.5 years. Only 48 (37.8%) of the female pharmacists aged 40 years or older underwent a mammogram. Knowledge of symptoms of breast cancer was the highest with a score of 755, followed by knowledge of risk factors (670) and finally early detection of breast cancer (540). Many barriers were reported by the community pharmacists including lack of educational materials and time constraints. Pharmacists with higher educational levels (p<0.001), of female gender (p<0.001), attended continuous cancer-related education (p<0.001), encountered a higher percentage of female customers (p<0.001), in a certain geographic location (p=0.003), underwent mammography (p=0.014), and encountered high frequency of inquiries on mammogram by the customers (p<0.001) were all associated with higher knowledge scores. Conclusion Despite the reported barriers and insufficient knowledge in certain aspects of early detection of breast cancer, community pharmacists have positive attitudes and can be a valuable asset for awareness-raising efforts.
Collapse
Affiliation(s)
- Lobna Gharaibeh
- Biopharmaceutics and Clinical Pharmacy Department, Al-Ahliyya Amman University, Amman, Jordan
| | - Mohammed Liswi
- Civilian Research and Development Foundation (CRDF) Global, Amman, Jordan
| | - Reem Al-Ajlouni
- Jordan Breast Cancer Program, King Hussein Cancer Foundation, Amman, Jordan
| | - Dina Shafei
- Jordan Breast Cancer Program, King Hussein Cancer Foundation, Amman, Jordan
| | | |
Collapse
|
2
|
Pace LE, Hagenimana M, Dusengimana JMV, Balinda JP, Benewe O, Rugema V, de Dieu Uwihaye J, Fata A, Shyirambere C, Shulman LN, Keating NL, Uwinkindi F. Implementation research: including breast examinations in a cervical cancer screening programme, Rwanda. Bull World Health Organ 2023; 101:478-486. [PMID: 37397178 PMCID: PMC10300777 DOI: 10.2471/blt.22.289599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 04/28/2023] [Accepted: 05/03/2023] [Indexed: 07/04/2023] Open
Abstract
Objective To evaluate whether integrating breast and cervical cancer screening in Rwanda's Women's Cancer Early Detection Program led to early breast cancer diagnoses in asymptomatic women. Methods Launched in three districts in 2018-2019, the early detection programme offered clinical breast examination screening for all women receiving cervical cancer screening, and diagnostic breast examination for women with breast cancer symptoms. Women with abnormal breast examinations were referred to district hospitals and then to referral hospitals if needed. We examined how often clinics were held, patient volumes and number of referrals. We also examined intervals between referrals and visits to the next care level and, among women diagnosed with cancer, their initial reasons for seeking care. Findings Health centres held clinics > 68% of the weeks. Overall, 9763 women received cervical cancer screening and clinical breast examination and 7616 received breast examination alone. Of 585 women referred from health centres, 436 (74.5%) visited the district hospital after a median of 9 days (interquartile range, IQR: 3-19). Of 200 women referred to referral hospitals, 179 (89.5%) attended after a median of 11 days (IQR: 4-18). Of 29 women diagnosed with breast cancer, 19 were ≥ 50 years and 23 had stage III or stage IV disease. All women with breast cancer whose reasons for seeking care were known (23 women) had experienced breast cancer symptoms. Conclusion In the short-term, integrating clinical breast examination with cervical cancer screening was not associated with detection of early-stage breast cancer among asymptomatic women. Priority should be given to encouraging women to seek timely care for symptoms.
Collapse
Affiliation(s)
- Lydia E Pace
- Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA02115, United States of America (USA)
| | | | | | | | | | | | | | - Amanda Fata
- Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA02115, United States of America (USA)
| | | | | | - Nancy L Keating
- Department of Health Care Policy, Harvard Medical School, Boston, USA
| | | |
Collapse
|
3
|
Sayed S, Ngugi AK, Nwosu N, Mutebi MC, Ochieng P, Mwenda AS, Salam RA. Training health workers in clinical breast examination for early detection of breast cancer in low- and middle-income countries. Cochrane Database Syst Rev 2023; 4:CD012515. [PMID: 37070783 PMCID: PMC10122521 DOI: 10.1002/14651858.cd012515.pub2] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
BACKGROUND Most women living in low- and middle-income countries (LMICs) present with advanced-stage breast cancer. Limitations of poor serviceable health systems, restricted access to treatment facilities, and lack of breast cancer screening programmes all likely contribute to the late presentation of women with breast cancer living in these countries. Women are diagnosed with advanced disease and frequently do not complete their care due to a number of factors, including financial reasons as health expenditure is largely out of pocket resulting in financial toxicity; health system failures, such as missing services or health worker lack of awareness on common signs and symptoms of cancer; and sociocultural barriers, such as stigma and use of alternative therapies. Clinical breast examination (CBE) is an inexpensive early detection technique for breast cancer in women with palpable breast masses. Training health workers from LMICs to conduct CBE has the potential to improve the quality of the technique and the ability of health workers to detect breast cancers early. OBJECTIVES To assess whether training in CBE affects the ability of health workers in LMICs to detect early breast cancer. SEARCH METHODS We searched the Cochrane Breast Cancer Specialised Registry, CENTRAL, MEDLINE, Embase, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal, and ClinicalTrials.gov up to 17 July 2021. SELECTION CRITERIA We included randomised controlled trials (RCTs) (including individual and cluster-RCTs), quasi-experimental studies and controlled before-and-after studies if they fulfilled the eligibility criteria. DATA COLLECTION AND ANALYSIS Two review authors independently screened studies for inclusion, and extracted data, assessed risk of bias, and assessed the certainty of the evidence using the GRADE approach. We performed statistical analysis using Review Manager software and presented the main findings of the review in a summary of findings table. MAIN RESULTS We included four RCTs that screened a total population of 947,190 women for breast cancer, out of which 593 breast cancers were diagnosed. All included studies were cluster-RCTs; two were conducted in India, one in the Philippines, and one in Rwanda. Health workers trained to perform CBE in the included studies were primary health workers, nurses, midwives, and community health workers. Three of the four included studies reported on the primary outcome (breast cancer stage at the time of presentation). Amongst secondary outcomes, included studies reported CBE coverage, follow-up, accuracy of health worker-performed CBE, and breast cancer mortality. None of the included studies reported knowledge attitude practice (KAP) outcomes and cost-effectiveness. Three studies reported diagnosis of breast cancer at early stage (at stage 0+I+II), suggesting that training health workers in CBE may increase the number of women detected with breast cancer at an early stage compared to the non-training group (45% detected versus 31% detected; risk ratio (RR) 1.44, 95% confidence interval (CI) 1.01 to 2.06; three studies; 593 participants; I2 = 0%; low-certainty evidence). Three studies reported diagnosis at late stage (III+IV) suggesting that training health workers in CBE may slightly reduce the number of women detected with breast cancer at late stage compared to the non-training group (13% detected versus 42%, RR 0.58, 95% CI 0.36 to 0.94; three studies; 593 participants; I2 = 52%; low-certainty evidence). Regarding secondary outcomes, two studies reported breast cancer mortality, implying that the evidence is uncertain for the impact on breast cancer mortality (RR 0.88, 95% CI 0.24 to 3.26; two studies; 355 participants; I2 = 68%; very low-certainty evidence). Due to the study heterogeneity, we could not conduct meta-analysis for accuracy of health worker-performed CBE, CBE coverage, and completion of follow-up, and therefore reported narratively using the 'Synthesis without meta-analysis' (SWiM) guideline. Sensitivity of health worker-performed CBE was reported to be 53.2% and 51.7%; while specificity was reported to be 100% and 94.3% respectively in two included studies (very low-certainty evidence). One trial reported CBE coverage with a mean adherence of 67.07% for the first four screening rounds (low-certainty evidence). One trial reported follow-up suggesting that compliance rates for diagnostic confirmation following a positive CBE were 68.29%, 71.20%, 78.84% and 79.98% during the respective first four rounds of screening in the intervention group compared to 90.88%, 82.96%, 79.56% and 80.39% during the respective four rounds of screening in the control group. AUTHORS' CONCLUSIONS Our review findings suggest some benefit of training health workers from LMICs in CBE on early detection of breast cancer. However, the evidence regarding mortality, accuracy of health worker-performed CBE, and completion of follow up is uncertain and requires further evaluation.
Collapse
Affiliation(s)
- Shahin Sayed
- Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Nairobi, Kenya
| | - Anthony K Ngugi
- Department of Population Health, Aga Khan University, Nairobi, Kenya
| | - Nicole Nwosu
- Department of Medical Sciences, Western University, London, Canada
| | - Miriam C Mutebi
- Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya
| | - Powell Ochieng
- Department of Post Graduate Medical Education, Aga Khan University, Nairobi, Kenya
| | | | - Rehana A Salam
- Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan
| |
Collapse
|
4
|
Nambaziira R, Niteka LC, Dusengimana JMV, Ruhumuriza J, Bhangdia KP, Mugunga JC, Uwineza ML, Rugema V, Erfani P, Shyirambere C, Shulman LN, Rabideau M, Pace LE. Health system costs of a breast cancer early diagnosis programme in a rural district of Rwanda: a retrospective, cross-sectional economic analysis. BMJ Open 2022; 12:e062357. [PMID: 35772820 PMCID: PMC9247687 DOI: 10.1136/bmjopen-2022-062357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVES This study aimed to quantify the health system cost of the first 2 years of a Breast Cancer Early Detection (BCED) programme in a rural district in Rwanda. We also aimed to estimate the cost of implementing the programme in other districts with different referral pathways and identify opportunities for enhanced cost efficiency. DESIGN Retrospective, cross-sectional analysis using time-driven activity-based costing, based on timed patient clinical encounters, retrospective patient data and unit costs of resources abstracted from administrative and finance records. SETTING The BCED programme focused on timely evaluation of individuals with breast symptoms. The study evaluated the health system cost of the BCED programme at seven health centres (HCs) in Burera district and Butaro Cancer Centre of Excellence (BCCOE) at Butaro District Hospital. OUTCOME MEASURES Health system costs per patient visit and cost per cancer diagnosed were quantified. Total start-up and recurring operational costs were also estimated, as well as health system costs of different scale-up adaptations in other districts. RESULTS One-time start-up costswere US$36 917, recurring operational costswere US$67 711 and clinical costswere US$14 824 over 2 years. Clinical breast examinations (CBE) at HCs cost US$3.27/visit. At BCCOE, CBE-only visits cost US$13.47/visit, CBE/ultrasound US$14.79/visit and CBE/ultrasound/biopsy/pathology US$147.81/visit. Overall, clinical cost per breast cancer diagnosed was US$1482. Clinicalcost drivers were personnel at HCs (55%) and biopsy/pathology supplies at BCCOE (46%). In other districts, patients experience a longer breast evaluation pathway, adding about US$14.00/patient; this could be decreased if ultrasound services were decentralised. CONCLUSION Clinical costs associated with BCED services at HCs were modest, similar to other general outpatient services. The BCED programme's start-up and operational costs were high but could be reduced by using local trainers and virtual mentorship. In other districts, decentralising ultrasound and/or biopsies to district hospitals could reduce costs.
Collapse
Affiliation(s)
| | | | | | | | | | - Jean Claude Mugunga
- Monitoring, Evaluation and Quality Improvement, Partners In Health, Arlington, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | | | | | - Parsa Erfani
- Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | - Lydia E Pace
- Brigham and Women's Hospital, Boston, Massachusetts, USA
| |
Collapse
|
5
|
Ward ZJ, Atun R, Hricak H, Asante K, McGinty G, Sutton EJ, Norton L, Scott AM, Shulman LN. The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. Lancet Oncol 2021; 22:1301-1311. [PMID: 34416159 DOI: 10.1016/s1470-2045(21)00403-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 06/21/2021] [Accepted: 06/30/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND Female breast cancer is the most commonly diagnosed cancer in the world, with wide variations in reported survival by country. Women in low-income and middle-income countries (LMICs) in particular face several barriers to breast cancer services, including diagnostics and treatment. We aimed to estimate the potential impact of scaling up the availability of treatment and imaging modalities on breast cancer survival globally, together with improvements in quality of care. METHODS For this simulation-based analysis, we used a microsimulation model of global cancer survival, which accounts for the availability and stage-specific survival impact of specific treatment modalities (chemotherapy, radiotherapy, surgery, and targeted therapy), imaging modalities (ultrasound, x-ray, CT, MRI, PET, and single-photon emission computed tomography [SPECT]), and quality of cancer care, to simulate 5-year net survival for women with newly diagnosed breast cancer in 200 countries and territories in 2018. We calibrated the model to empirical data on 5-year net breast cancer survival in 2010-14 from CONCORD-3. We evaluated the potential impact of scaling up specific imaging and treatment modalities and quality of care to the mean level of high-income countries, individually and in combination. We ran 1000 simulations for each policy intervention and report the means and 95% uncertainty intervals (UIs) for all model outcomes. FINDINGS We estimate that global 5-year net survival for women diagnosed with breast cancer in 2018 was 67·9% (95% UI 62·9-73·4) overall, with an almost 25-times difference between low-income (3·5% [0·4-10·0]) and high-income (87·0% [85·6-88·4]) countries. Among individual treatment modalities, scaling up access to surgery alone was estimated to yield the largest survival gains globally (2·7% [95% UI 0·4-8·3]), and scaling up CT alone would have the largest global impact among imaging modalities (0·5% [0·0-2·0]). Scaling up a package of traditional modalities (surgery, chemotherapy, radiotherapy, ultrasound, and x-ray) could improve global 5-year net survival to 75·6% (95% UI 70·6-79·4), with survival in low-income countries improving from 3·5% (0·4-10·0) to 28·6% (4·9-60·1). Adding concurrent improvements in quality of care could further improve global 5-year net survival to 78·2% (95% UI 74·9-80·4), with a substantial impact in low-income countries, improving net survival to 55·3% (42·2-67·8). Comprehensive scale-up of access to all modalities and improvements in quality of care could improve global 5-year net survival to 82·3% (95% UI 79·3-85·0). INTERPRETATION Comprehensive scale-up of treatment and imaging modalities, and improvements in quality of care could improve global 5-year net breast cancer survival by nearly 15 percentage points. Scale-up of traditional modalities and quality-of-care improvements could achieve 70% of these total potential gains, with substantial impact in LMICs, providing a more feasible pathway to improving breast cancer survival in these settings even without the benefits of future investments in targeted therapy and advanced imaging. FUNDING Harvard T H Chan School of Public Health, and National Cancer Institute P30 Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center.
Collapse
Affiliation(s)
- Zachary J Ward
- Center for Health Decision Science, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
| | - Rifat Atun
- Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA
| | - Hedvig Hricak
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Kwanele Asante
- African Organisation for Research and Training in Cancer, Cape Town, South Africa
| | - Geraldine McGinty
- Departments of Radiology and Population Science, Weill Cornell Medical College, New York, NY, USA
| | - Elizabeth J Sutton
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Larry Norton
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Andrew M Scott
- Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
| | - Lawrence N Shulman
- Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
6
|
O'Neil DS, Nxumalo S, Ngcamphalala C, Tharp G, Jacobson JS, Nuwagaba-Biribonwoha H, Dlamini X, Pace LE, Neugut AI, Harris TG. Breast Cancer Early Detection in Eswatini: Evaluation of a Training Curriculum and Patient Receipt of Recommended Follow-Up Care. JCO Glob Oncol 2021; 7:1349-1357. [PMID: 34491814 PMCID: PMC8423396 DOI: 10.1200/go.21.00124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 06/08/2021] [Accepted: 08/02/2021] [Indexed: 02/06/2023] Open
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Daniel S. O'Neil
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
| | - Sifiso Nxumalo
- ICAP at Columbia University Mailman School of Public Health, New York, NY
| | | | - G Tharp
- ICAP at Columbia University Mailman School of Public Health, New York, NY
| | | | | | | | - Lydia E. Pace
- Brigham and Women's Hospital, Harvard University, Boston, MA
| | - Alfred I. Neugut
- Mailman School of Public Health, Columbia University, New York, NY
- Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - Tiffany G. Harris
- ICAP at Columbia University Mailman School of Public Health, New York, NY
| |
Collapse
|
7
|
Rubagumya F, Costas-Chavarri A, Manirakiza A, Murenzi G, Uwinkindi F, Ntizimira C, Rukundo I, Mugenzi P, Rugwizangoga B, Shyirambere C, Urusaro S, Pace L, Buswell L, Ntirenganya F, Rudakemwa E, Fadelu T, Mpunga T, Shulman LN, Booth CM. State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. JCO Glob Oncol 2021; 6:1171-1177. [PMID: 32701365 PMCID: PMC7392739 DOI: 10.1200/go.20.00281] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Rwanda is a densely populated low-income country in East Africa. Previously considered a failed state after the genocide against the Tutsi in 1994, Rwanda has seen remarkable growth over the past 2 decades. Health care in Rwanda is predominantly delivered through public hospitals and is emerging in the private sector. More than 80% of patients are covered by community-based health insurance (Mutuelle de Santé). The cancer unit at the Rwanda Biomedical Center (a branch of the Ministry of Health) is responsible for setting and implementing cancer care policy. Rwanda has made progress with human papillomavirus (HPV) and hepatitis B vaccination. Recently, the cancer unit at the Rwanda Biomedical Center launched the country’s 5-year National Cancer Control Plan. Over the past decade, patients with cancer have been able to receive chemotherapy at Butaro Cancer Center, and recently, the Rwanda Cancer Center was launched with 2 linear accelerator radiotherapy machines, which greatly reduced the number of referrals for treatment abroad. Palliative care services are increasing in Rwanda. A cancer registry has now been strengthened, and more clinicians are becoming active in cancer research. Despite these advances, there is still substantial work to be done and there are many outstanding challenges, including the need to build capacity in cancer awareness among the general population (and shift toward earlier diagnosis), cancer care workforce (more in-country training programs are needed), and research.
Collapse
Affiliation(s)
- Fidel Rubagumya
- Department of Oncology, Rwanda Military Hospital, Kigali, Rwanda.,University of Global Health Equity, Burera, Rwanda
| | | | | | - Gad Murenzi
- Department of Research, Rwanda Military Hospital, Kigali, Rwanda
| | | | | | - Ivan Rukundo
- Department of Radiology, Rwanda Military Hospital, Kigali, Rwanda
| | | | - Belson Rugwizangoga
- Department of Pathology, Kigali University Teaching Hospital, Kigali, Rwanda
| | | | - Sandra Urusaro
- Department of Oncology, Inshuti Mu Buzima, Kigali, Rwanda
| | - Lydia Pace
- Division of Women's Health, Brigham and Women's Hospital, Boston, MA
| | - Lori Buswell
- Department of Oncology, Dana-Farber Cancer Institute, Boston, MA
| | | | | | - Temidayo Fadelu
- Department of Oncology, Dana-Farber Cancer Institute, Boston, MA
| | | | - Lawrence N Shulman
- Center for Global Cancer Medicine, University of Pennsylvania, Philadelphia, PA
| | | |
Collapse
|
8
|
Implementing Cancer Care in Rwanda: Capacity Building for Treatment and Scale-Up. SUSTAINABILITY 2021. [DOI: 10.3390/su13137216] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: The majority of countries in sub-Saharan Africa are ill-prepared to address the rising burden of cancer. While some have been able to establish a single cancer referral center, few have been able to scale-up services nationally towards universal health coverage. The literature lacks a step-wise implementation approach for resource-limited countries to move beyond a single-facility implementation strategy and implement a national cancer strategy to expand effective coverage. Methods: We applied an implementation science framework, which describes a four-phase approach: Exploration, Preparation, Implementation, and Sustainment (EPIS). Through this framework, we describe Rwanda’s approach to establish not just a single cancer center, but a national cancer program. Results: By applying EPIS to Rwanda’s implementation approach, we analyzed and identified the implementation strategies and factors, which informed processes of each phase to establish foundational cancer delivery components, including trained staff, diagnostic technology, essential medicines, and medical informatics. These cancer delivery components allowed for the implementation of Rwanda’s first cancer center, while simultaneously serving as the nidus for capacity building of foundational components for future cancer centers. Conclusion: This “progressive scaling” approach ensured that initial investments in the country’s first cancer center was a step toward establishing future cancer centers in the country.
Collapse
|
9
|
O'Donovan J, Newcomb A, MacRae MC, Vieira D, Onyilofor C, Ginsburg O. Community health workers and early detection of breast cancer in low-income and middle-income countries: a systematic scoping review of the literature. BMJ Glob Health 2021; 5:bmjgh-2020-002466. [PMID: 32409331 PMCID: PMC7228495 DOI: 10.1136/bmjgh-2020-002466] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Revised: 04/15/2020] [Accepted: 04/17/2020] [Indexed: 12/24/2022] Open
Abstract
Background Breast cancer is the leading cause of female mortality in low-income and middle-income countries (LMICs). Early detection of breast cancer, either through screening or early diagnosis initiatives, led by community health workers (CHWs) has been proposed as a potential way to address the unjustly high mortality rates. We therefore document: (1) where and how CHWs are currently deployed in this role; (2) how CHWs are trained, including the content, duration and outcomes of training; and (3) the evidence on costs associated with deploying CHWs in breast cancer early detection. Methods We conducted a systematic scoping review and searched eight major databases, as well as the grey literature. We included original studies focusing on the role of CHWs to assist in breast cancer early detection in a country defined as a LMIC according to the World Bank. Findings 16 eligible studies were identified. Several roles were identified for CHWs including awareness raising and community education (n=13); history taking (n=7); performing clinical breast examination (n=9); making onward referrals (n=7); and assisting in patient navigation and follow-up (n=4). Details surrounding training programmes were poorly reported and no studies provided a formal cost analysis. Conclusions Despite the relative paucity of studies addressing the role of CHWs in breast cancer early detection, as well as the heterogeneity of existing studies, evidence suggests that CHWs can play a number of important roles in breast cancer early detection initiatives in LMICs. However, if they are to realise their full potential, they must be appropriately supported within the wider health system.
Collapse
Affiliation(s)
- James O'Donovan
- Department of Education, Oxford University, Oxford, Oxfordshire, UK .,Division of Research and Health Equity, Omni Med, Mukono, Uganda
| | - Ashley Newcomb
- Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA
| | - MacKenzie Clark MacRae
- Division of Research and Health Equity, Omni Med, Mukono, Uganda.,Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA
| | - Dorice Vieira
- Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA
| | - Chinelo Onyilofor
- The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Ophira Ginsburg
- Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York, USA
| |
Collapse
|
10
|
Hand T, Rosseau NA, Stiles CE, Sheih T, Ghandakly E, Oluwasanu M, Olopade OI. The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. Glob Health Action 2021; 14:1883336. [PMID: 33899695 PMCID: PMC8079044 DOI: 10.1080/16549716.2021.1883336] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Introduction: Innovative interventions are needed to address the growing burden of breast cancer globally, especially among vulnerable patient populations. Given the success of Community Health Workers (CHWs) in addressing communicable diseases and non-communicable diseases, this scoping review will investigate the roles and impacts of CHWs in breast cancer screening programs. This paper also seeks to determine the effectiveness and feasibility of these programs, with particular attention paid to differences between CHW-led interventions in low- and middle-income countries (LMICs) and high-income countries (HICs).Methods: A scoping review was performed using six databases with dates ranging from 1978 to 2019. Comprehensive definitions and search terms were established for ‘Community Health Workers’ and ‘breast cancer screening’, and studies were extracted using the World Bank definition of LMIC. Screening and data extraction were protocolized using multiple independent reviewers. Chi-square test of independence was used for statistical analysis of the incidence of themes in HICs and LMICs.Results: Of the 1,551 papers screened, 33 were included based on inclusion and exclusion criteria. Study locations included the United States (n=27), Bangladesh (n=1), Peru (n=1), Malawi (n=2), Rwanda (n=1), and South Africa (n=1). Three primary roles for CHWs in breast cancer screening were identified: education (n=30), direct assistance or performance of breast cancer screening (n=7), and navigational services (n=6). In these roles, CHWs improved rates of breast cancer screening (n=23) and overall community member knowledge (n=21). Two studies performed cost-analyses of CHW-led interventions.Conclusion: This review extends our understanding of CHW effectiveness to breast cancer screening. It illustrates how CHW involvement in screening programs can have a significant impact in LMICs and HICs, and highlights the three CHW roles of education, direct performance of screening, and navigational services that emerge as useful pillars around which governments and NGOs can design effective programs in this area.
Collapse
Affiliation(s)
- Taylor Hand
- School of Medicine and Health Sciences, The George Washington University, Washington, USA
| | - Natalie A Rosseau
- School of Medicine and Health Sciences, The George Washington University, Washington, USA
| | | | - Tianna Sheih
- School of Medicine and Health Sciences, The George Washington University, Washington, USA
| | - Elizabeth Ghandakly
- School of Medicine and Health Sciences, The George Washington University, Washington, USA
| | - Mojisola Oluwasanu
- Department of Health Promotion & Education, Faculty of Public Health, University of Ibadan, Ibadan, Nigeria
| | - Olufunmilayo I Olopade
- Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.,Center for Clinical Cancer Genetics & Global Health, The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
| |
Collapse
|
11
|
Abstract
Background: Cervical cancer is among the most common cancers affecting women globally. Where treatment is available in low- and middle-income countries, many women become lost to follow-up (LTFU) at various points of care. Objective: This study assessed predictors of LTFU among cervical cancer patients in rural Rwanda. Methods: We conducted a retrospective study of cervical cancer patients enrolled at Butaro Cancer Center of Excellence (BCCOE) between 2012 and 2017 who were either alive and in care or LTFU at 12 months after enrollment. Patients are considered early LTFU if they did not return to clinic after the first visit and late LTFU if they did not return to clinic after the second visit. We conducted two multivariable logistic regressions to determine predictors of early and late LTFU. Findings: Of 652 patients in the program, 312 women met inclusion criteria, of whom 47 (15.1%) were early LTFU, 78 (25.0%) were late LTFU and 187 (59.9%) were alive and in care. In adjusted analyses, patients with no documented disease stage at presentation were more likely to be early LTFU vs. patients with stage 1 and 2 when controlling for other factors (aOR: 14.93, 95% CI 6.12–36.43). Patients who travel long distances (aOR: 2.25, 95% CI 1.11, 4.53), with palliative care as type of treatment received (aOR: 6.65, CI 2.28, 19.40) and patients with missing treatment (aOR: 7.99, CI 3.56, 17.97) were more likely to be late LTFU when controlling for other factors. Patients with ECOG status of 2 and higher were less likely to be late LTFU (aOR: 0.26, 95% CI 0.08, 0.85). Conclusion: Different factors were associated with early and later LTFU. Enhanced patient education, mechanisms to facilitate diagnosis at early stages of disease, and strategies that improve patient tracking and follow-up may reduce LTFU and improve patient retention.
Collapse
|
12
|
Uwayezu MG, Sego R, Nikuze B, Fitch M. Oncology nursing education and practice: looking back, looking forward and Rwanda's perspective. Ecancermedicalscience 2020; 14:1079. [PMID: 32863873 PMCID: PMC7434500 DOI: 10.3332/ecancer.2020.1079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Oncology care is a highly specialised division of nursing which requires a higher level of training and education following basic preparation. Rwanda, a developing country, initiated education of oncology nurse specialists in 2015. This paper highlights the experience of establishing the programme. METHODS Selected literature and expert oncology nurses were consulted to provide direction for the development of this paper. The websites of oncology nursing organisations and the curriculum used by the University of Rwanda for preparing oncology nurses were also reviewed. RESULTS In 2015, Rwanda initiated the training of oncology nurse specialists (master's level). The programme has had two successful cohorts graduating. This programme is implemented in a module system with 14 modules. The modules emphasised on screening and diagnosis of different cancers and their treatment, management of treatment related side effects, palliative care, end-of-life care and rehabilitation. A part this formal education, Rwanda, through Partners in Health and the Rwanda Biomedical Center, is also offering in-service training of nurses on cancer treatment, preventive measures and early identification such as Clinical Breast Examination and screening of cervical cancer. CONCLUSION Oncology nurses can play a key role in the care of cancer patients and prevention activities when they have the appropriate education. Rwanda's experience in establishing a master's programme in oncology nursing could be of assistance to others who wish to develop a similar programme.
Collapse
Affiliation(s)
- Marie Goretti Uwayezu
- School of Nursing and Midwifery University of Rwanda, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
| | - Ruth Sego
- School of Nursing and Midwifery University of Rwanda, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
- Rory Meyer’s College of Nursing, New York University, New York, USA
| | - Bellancille Nikuze
- School of Nursing and Midwifery University of Rwanda, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
| | - Margaret Fitch
- School of Nursing and Midwifery University of Rwanda, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
- Rory Meyer’s College of Nursing, New York University, New York, USA
| |
Collapse
|
13
|
Pace LE, Dusengimana JMV, Shulman LN, Schleimer LE, Shyirambere C, Rusangwa C, Muvugabigwi G, Park PH, Huang C, Bigirimana JB, Hategekimana V, Rugema V, Umwizerwa A, Keating NL, Mpunga T. Cluster Randomized Trial to Facilitate Breast Cancer Early Diagnosis in a Rural District of Rwanda. J Glob Oncol 2020; 5:1-13. [PMID: 31774713 PMCID: PMC6882507 DOI: 10.1200/jgo.19.00209] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PURPOSE Feasible and effective strategies are needed to facilitate earlier diagnosis of breast cancer in low-income countries. The goal of this study was to examine the impact of health worker breast health training on health care utilization, patient diagnoses, and cancer stage in a rural Rwandan district. METHODS We conducted a cluster randomized trial of a training intervention at 12 of the 19 health centers (HCs) in Burera District, Rwanda, in 2 phases. We evaluated the trainings’ impact on the volume of patient visits for breast concerns using difference-in-difference models. We used generalized estimating equations to evaluate incidence of HC and hospital visits for breast concerns, biopsies, benign breast diagnoses, breast cancer, and early-stage disease in catchment areas served by intervention versus control HCs. RESULTS From April 2015 to April 2017, 1,484 patients visited intervention HCs, and 308 visited control HCs for breast concerns. The intervention led to an increase of 4.7 visits/month for phase 1 HCs (P = .001) and 7.9 visits/month for phase 2 HCs (P = .007) compared with control HCs. The population served by intervention HCs had more hospital visits (115.1 v 20.5/100,000 person-years, P < .001) and biopsies (36.6 v 8.9/100,000 person-years, P < .001) and higher breast cancer incidence (6.9 v 3.3/100,000 person-years; P = .28). The incidence of early-stage breast cancer was 3.3 per 100,000 in intervention areas and 0.7 per 100,000 in control areas (P = .048). CONCLUSION In this cluster randomized trial in rural Rwanda, the training of health workers and establishment of regular breast clinics were associated with increased numbers of patients who presented with breast concerns at health facilities, more breast biopsies, and a higher incidence of benign breast diagnoses and early-stage breast cancers.
Collapse
Affiliation(s)
- Lydia E Pace
- Brigham and Women's Hospital, Boston, MA.,Harvard Medical School, Boston, MA
| | | | | | | | | | | | | | - Paul H Park
- Brigham and Women's Hospital, Boston, MA.,Harvard Medical School, Boston, MA
| | - ChuanChin Huang
- Brigham and Women's Hospital, Boston, MA.,Harvard Medical School, Boston, MA
| | | | | | | | | | - Nancy L Keating
- Brigham and Women's Hospital, Boston, MA.,Harvard Medical School, Boston, MA
| | | |
Collapse
|
14
|
Hanappe M, Nicholson LT, Elmore SNC, Fehr AE, Bigirimana JB, Borg RC, Butonzi J, Shyirambere C, Mpanumusingo E, Benewe MO, Kanyike DM, Triedman S, Shulman LN, Rusangwa C, Park PH. International Radiotherapy Referrals From Rural Rwanda: Implementation Processes and Early Clinical Outcomes. J Glob Oncol 2019; 4:1-12. [PMID: 30321096 PMCID: PMC7010442 DOI: 10.1200/jgo.18.00089] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Purpose Low- and middle-income countries disproportionately comprise 65% of cancer deaths. Cancer care delivery in resource-limited settings, especially low-income countries in sub-Saharan Africa, is exceedingly complex, requiring multiple modalities of diagnosis and treatment. Given the vast human, technical, and financial resources required, access to radiotherapy remains limited in sub-Saharan Africa. Through 2017, Rwanda has not had in-country radiotherapy services. The aim of this study was to describe the implementation and early outcomes of the radiotherapy referral program at the Butaro Cancer Centre of Excellence and to identify both successful pathways and barriers to care. Methods Butaro District Hospital is located in a rural area of the Northern Province and is home to the Butaro Cancer Centre of Excellence. We performed a retrospective study from routinely collected data of all patients with a diagnosis of cervical, head and neck, or rectal cancer between July 2012 and June 2015. Results Between 2012 and 2015, 580 patients were identified with these diagnoses and were potential candidates for radiation. Two hundred eight (36%) were referred for radiotherapy treatment in Uganda. Of those referred, 160 (77%) had cervical cancer, 31 (15%) had head and neck cancer, and 17 (8%) had rectal cancer. At the time of data collection, 101 radiotherapy patients (49%) were alive and had completed treatment with no evidence of recurrence, 11 (5%) were alive and continuing treatment, and 12 (6%) were alive and had completed treatment with evidence of recurrence. Conclusion This study demonstrates the feasibility of a rural cancer facility to successfully conduct out-of-country radiotherapy referrals with promising early outcomes. The results of this study also highlight the many challenges and lessons learned in providing comprehensive cancer care in resource-limited settings.
Collapse
Affiliation(s)
- Maud Hanappe
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Lowell T Nicholson
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Shekinah N C Elmore
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Alexandra E Fehr
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Jean Bosco Bigirimana
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Ryan C Borg
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - John Butonzi
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Cyprien Shyirambere
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Egide Mpanumusingo
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Marie O Benewe
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Dan M Kanyike
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Scott Triedman
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Lawrence N Shulman
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Christian Rusangwa
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| | - Paul H Park
- Maud Hanappe, Free University of Brussels, Brussels, Belgium; Lowell T. Nicholson, Duke University School of Medicine, Durham, NC; Shekinah N.C. Elmore, Harvard Radiation Oncology Program; Shekinah N.C. Elmore and Paul H. Park, Harvard Medical School; Ryan C. Borg, Boston College School of Social Work; Paul H. Park, Brigham and Women's Hospital; Paul H. Park, Partners in Health, Boston, MA; Alexandra E. Fehr, Jean Bosco Bigirimana, Cyprien Shyirambere, Egide Mpanumusingo, Marie O. Benewe, and Christian Rusangwa, Inshuti mu Buzima/Partners in Health; John Butonzi, Butaro District Hospital, Rwanda Ministry of Health, Butaro, Rwanda; Dan M. Kanyike, Uganda Cancer Institute, Kampala, Uganda; Scott Triedman, The Warren Alpert Medical School of Brown University, Providence, RI; and Lawrence N. Shulman, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
15
|
Gebremariam A, Addissie A, Worku A, Assefa M, Kantelhardt EJ, Jemal A. Perspectives of patients, family members, and health care providers on late diagnosis of breast cancer in Ethiopia: A qualitative study. PLoS One 2019; 14:e0220769. [PMID: 31369640 PMCID: PMC6675093 DOI: 10.1371/journal.pone.0220769] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Accepted: 07/23/2019] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Most women with breast cancer in Ethiopia are diagnosed at an advanced stage of the disease, but the reasons for this have not been systematically investigated. This study, therefore, aimed to explore the main reasons for diagnosis of advanced stage breast cancer from the perspective of patients, family members, and health care providers. METHODS A qualitative study with in-depth interviews was conducted with 23 selected participants at Tikur Anbessa Specialized Hospital, Oncology Clinic using a semi-structured interview guide. These participants were 13 breast cancer patients, 5 family members, and 5 health care providers. Data were transcribed into English, coded and analyzed using thematic analysis. RESULTS Awareness about the causes, risk, initial symptoms, early detection methods, and treatment of breast cancer were uncommon, and misconceptions about the disease prevailed among breast cancer patients and family members. There was a sense of hopelessness and uncertainty about the effectiveness of conventional medicine amongst patients and family members. Consequently, performing spiritual acts (using holy water) or seeking care from traditional healers recurred amongst the interviewees. Not taking initial symptoms of breast cancer seriously by the patients, reliance on traditional medicines, competing priorities, financial hardship, older age, fear of diagnosis of cancer, and weak health systems (e.g., delay in referral and long waiting period for consultation) were noted as the main contributors to late diagnosis. In contrast, persuasion by family members and friends, higher educational attainment, and prior experience of neighboring women with breast cancer were mentioned to be facilitators of early diagnosis of breast cancer. CONCLUSIONS The causes of late diagnosis of breast cancer in Ethiopia are multi-factorial and include individual, cultural, and health system factors. Interventions targeting these factors could alleviate the misconceptions and knowledge gap about breast cancer in the community, and shorten waiting time between symptom recognition and diagnosis of breast cancer.
Collapse
Affiliation(s)
- Alem Gebremariam
- Department of Public Health, College of Medicine and Health Sciences, Adigrat University, Adigrat, Ethiopia
- School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
| | - Adamu Addissie
- School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
| | - Alemayehu Worku
- School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
| | - Mathewos Assefa
- Radiotherapy Center, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | - Eva Johanna Kantelhardt
- Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University, Halle, Germany
| | - Ahmedin Jemal
- Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, United States of America
| |
Collapse
|
16
|
Martin AN, Kaneza KM, Kulkarni A, Mugenzi P, Ghebre R, Ntirushwa D, Ilbawi AM, Pace LE, Costas-Chavarri A. Cancer Control at the District Hospital Level in Sub-Saharan Africa: An Educational and Resource Needs Assessment of General Practitioners. J Glob Oncol 2019; 5:1-8. [PMID: 30668270 PMCID: PMC6426480 DOI: 10.1200/jgo.18.00126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
PURPOSE The WHO framework for early cancer diagnosis highlights the need to improve health care capacity among primary care providers. In Rwanda, general practitioners (GPs) at district hospitals (DHs) play key roles in diagnosing, initiating management, and referring suspected patients with cancer. We sought to ascertain educational and resource needs of GPs to provide a blueprint that can inform future early cancer diagnosis capacity–building efforts. METHODS We administered a cross-sectional survey study to GPs practicing in 42 Rwandan DHs to assess gaps in cancer-focused knowledge, skills, and resources, as well as delays in the referral process. Responses were aggregated and descriptive analysis was performed to identify trends. RESULTS Survey response rate was 76% (73 of 96 GPs). Most responders were 25 to 29 years of age (n = 64 [88%]) and 100% had been practicing between 3 and 12 months. Significant gaps in cancer knowledge and physical exam skills were identified—88% of respondents were comfortable performing breast exams, but less than 10 (15%) GPs reported confidence in performing pelvic exams. The main educational resource requested by responders (n = 59 [81%]) was algorithms to guide clinical decision-making. Gaps in resource availability were identified, with only 39% of responders reporting breast ultrasound availability and 5.8% reporting core needle biopsy availability in DHs. Radiology and pathology resources were limited, with 52 (71%) reporting no availability of pathology services at the DH level. CONCLUSION The current study reveals significant basic oncologic educational and resource gaps in Rwanda, such as physical examination skills and diagnostic tools. Capacity building for GPs in low- and middle-income countries should be a core component of national cancer control plans to improve accurate and timely diagnosis of cancer. Continuing professional development activities should address and focus on context-specific educational gaps, resource availability, and referral practice guidelines.
Collapse
Affiliation(s)
| | | | | | | | - Rahel Ghebre
- University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda.,University of Minnesota Medical School, Minneapolis, MN.,Yale School of Medicine, New Haven, CT
| | - David Ntirushwa
- University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda
| | | | | | - Ainhoa Costas-Chavarri
- Rwanda Military Hospital, Kigali, Rwanda.,Yale School of Medicine, New Haven, CT.,Boston Children's Hospital, Boston, MA
| |
Collapse
|